OverviewSuggest Edit

AnaptysBio is a biotechnology company developing immunology therapeutic product candidates. It focuses on immune control mechanisms applicable to inflammation and immuno-oncology indications. The company offers ANB019, ANB030, and ANB032 antibody programs to address inflammatory disorders.
TypePublic
Founded2005
HQSan Diego, CA, US
Websiteanaptysbio.com
Employee Ratings3.8

Latest Updates

Employees (est.) (Dec 2019)89(-8%)
Job Openings21
Revenue (FY, 2020)$75 M(+838%)
Share Price (Sept 2021)$26.8
Cybersecurity ratingBMore

Key People/Management at AnaptysBio

Hamza Suria

Hamza Suria

President and CEO, Director
Paul F. Lizzul

Paul F. Lizzul

Chief Medical Officer
Eric Loumeau

Eric Loumeau

Chief Operating Officer
Beth Mueller

Beth Mueller

Senior Vice President, Human Resources
Dennis Mulroy

Dennis Mulroy

Chief Financial Officer
Margaret Marino

Margaret Marino

Senior Vice President, Project Management
Show more

AnaptysBio Office Locations

AnaptysBio has an office in San Diego
San Diego, CA, US (HQ)
10421 Pacific Center Ct Suite 200
Show all (1)

AnaptysBio Financials and Metrics

AnaptysBio Revenue

AnaptysBio's revenue was reported to be $75 m in FY, 2020
USD

Revenue (Q1, 2021)

11.2m

Net income (Q1, 2021)

(18.2m)

EBIT (Q1, 2021)

(18.4m)

Market capitalization (6-Sept-2021)

735.2m

Closing stock price (6-Sept-2021)

26.8

Cash (31-Mar-2021)

284.1m

EV

451.5m
AnaptysBio's current market capitalization is $735.2 m.
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Revenue

10.0m5.0m8.0m75.0m

General and administrative expense

9.3m15.5m16.1m18.9m

R&D expense

29.4m56.2m99.3m80.0m

Operating expense total

38.8m71.7m115.4m98.9m
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Revenue

7.0m5.0m5.0m15.0m11.2m

General and administrative expense

2.1m2.4m2.4m3.9m3.8m4.0m4.1m4.3m3.8m4.3m4.7m4.8m5.4m

R&D expense

7.9m7.2m6.7m11.8m10.6m17.9m20.6m27.4m29.9m21.0m17.9m19.5m24.2m

Operating expense total

10.0m9.6m9.1m15.8m14.4m21.9m24.8m31.7m33.7m25.3m22.6m24.3m29.6m
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Cash

81.2m113.6m171.0m250.5m

Accounts Receivable

Prepaid Expenses

2.7m7.0m3.5m2.9m

Current Assets

252.7m434.2m377.7m396.6m
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Cash

96.8m30.8m26.7m69.5m57.1m293.4m105.9m146.6m182.9m165.3m221.2m209.2m284.1m

Accounts Receivable

5.0m5.0m5.0m1.2m

Prepaid Expenses

1.7m3.9m3.1m2.2m3.8m4.0m6.1m3.8m3.6m3.6m6.6m7.5m5.5m

Current Assets

110.2m115.8m120.3m251.9m271.8m503.0m421.9m431.0m424.6m371.1m384.5m345.8m387.1m
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(30.1m)(61.7m)(97.3m)(19.9m)

Depreciation and Amortization

183.0k315.0k514.0k559.0k

Accounts Payable

2.2m7.1m14.5m(8.9m)

Cash From Operating Activities

(19.4m)(48.5m)(69.5m)(14.2m)
USDQ1, 2017

Financial Leverage

1.2 x
Show all financial metrics

AnaptysBio Cybersecurity Score

Cybersecurity ratingPremium dataset

B

89/100

SecurityScorecard logo

AnaptysBio Online and Social Media Presence

Embed Graph

AnaptysBio News and Updates

Global Netherton Syndrome Market 2021-2030 Featuring Major Players - Lifemax Laboratories and AnaptysBio

Dublin, Aug. 12, 2021 (GLOBE NEWSWIRE) -- The "Netherton Syndrome Market Insight, Epidemiology and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering. This 'Netherton Syndrome - Market Insights, Epidemiology, and Market Forecast - 2030' report delivers an in-depth u…

AnaptysBio Announces Appointment of Oleg Nodelman to Board of Directors

SAN DIEGO, April 12, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced the …

AnaptysBio Reports Imsidolimab POPLAR Phase 2 Clinical Trial in Moderate-to-Severe Palmoplantar Pustulosis (PPP) Did Not Meet Primary Endpoint

SAN DIEGO, March 08, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced that…

AnaptysBio to Present at the 39th Annual J.P. Morgan Healthcare Conference

SAN DIEGO, Jan. 07, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced that …

AnaptysBio to Present at the 2020 Jefferies London Virtual Healthcare Conference

SAN DIEGO, Nov. 13, 2020 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced that …

AnaptysBio Announces Third Quarter 2020 Financial Results and Provides Pipeline Updates

SAN DIEGO, Nov. 04, 2020 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today reported operat…
Show more

AnaptysBio Blogs

AnaptysBio to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference

AnaptysBio to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference Content Import Thu, 09/09/2021 - 16:05 AnaptysBio to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference Sep 09, 2021 This release is a backfill …

Preclinical characterization of dostarlimab, a therapeutic anti-PD-1 antibody with potent activity to enhance immune function in in vitro cellular assays and in vivo animal models

Kumar et al. MAbs. 2021 July 13(1):e1954136. doi:10.1080/19420862.2021.1954136. The post Preclinical characterization of dostarlimab, a therapeutic anti-PD-1 antibody with potent activity to enhance immune function in in vitro cellular assays and in vivo animal models appeared first on AnaptysBio.

FDA Grants Accelerated Approval of JEMPERLI (dostarlimab-gxly) for dMMR Recurrent or Advanced Solid Tumors

The post FDA Grants Accelerated Approval of JEMPERLI (dostarlimab-gxly) for dMMR Recurrent or Advanced Solid Tumors appeared first on AnaptysBio.

FDA Grants Accelerated Approval of JEMPERLI (dostarlimab-gxly) for dMMR Recurrent or Advanced Solid Tumors

Second FDA Approval of PD-1 Antagonist Antibody Under Clinical Development for Solid Tumors in Collaboration with GSK JEMPERLI Was Approved For dMMR Endometrial Cancer in the US and Europe in April 2021 $20MM Milestone Payment Earned by AnaptysBio Upon Second JEMPERLI FDA Approval in Addition to

AnaptysBio Announces Second Quarter 2021 Financial Results and Provides Pipeline Updates

The post AnaptysBio Announces Second Quarter 2021 Financial Results and Provides Pipeline Updates appeared first on AnaptysBio.

AnaptysBio Announces Second Quarter 2021 Financial Results and Provides Pipeline Updates

Imsidolimab GPP GEMINI-1 Phase 3 trial anticipated to initiate in Q3 2021 following recent FDA end-of-Phase 2 Meeting Imsidolimab GALLOP GPP Phase 2 trial 16-week data to be orally presented at the EADV Congress on October 2 nd , 2021 Imsidolimab Phase 2 trials ongoing in acne, hidradenitis
Show more

AnaptysBio Frequently Asked Questions

  • When was AnaptysBio founded?

    AnaptysBio was founded in 2005.

  • Who are AnaptysBio key executives?

    AnaptysBio's key executives are Hamza Suria, Paul F. Lizzul and Eric Loumeau.

  • How many employees does AnaptysBio have?

    AnaptysBio has 89 employees.

  • What is AnaptysBio revenue?

    Latest AnaptysBio annual revenue is $75 m.

  • What is AnaptysBio revenue per employee?

    Latest AnaptysBio revenue per employee is $842.7 k.

  • Who are AnaptysBio competitors?

    Competitors of AnaptysBio include Zelluna Immunotherapy, Immunwork and Exonate.

  • Where is AnaptysBio headquarters?

    AnaptysBio headquarters is located at 10421 Pacific Center Ct Suite 200, San Diego.

  • Where are AnaptysBio offices?

    AnaptysBio has an office in San Diego.

  • How many offices does AnaptysBio have?

    AnaptysBio has 1 office.